MX2020006587A - Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. - Google Patents
Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.Info
- Publication number
- MX2020006587A MX2020006587A MX2020006587A MX2020006587A MX2020006587A MX 2020006587 A MX2020006587 A MX 2020006587A MX 2020006587 A MX2020006587 A MX 2020006587A MX 2020006587 A MX2020006587 A MX 2020006587A MX 2020006587 A MX2020006587 A MX 2020006587A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- sub
- phosphate kinase
- aminopyridine derivatives
- phosphatidylinositol phosphate
- Prior art date
Links
- 150000003927 aminopyridines Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 150000003907 phosphatidylinositol monophosphates Chemical class 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609568P | 2017-12-22 | 2017-12-22 | |
| PCT/US2018/067264 WO2019126731A1 (en) | 2017-12-22 | 2018-12-21 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006587A true MX2020006587A (es) | 2020-12-10 |
Family
ID=65041934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006587A MX2020006587A (es) | 2017-12-22 | 2018-12-21 | Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11667651B2 (enExample) |
| EP (1) | EP3728228A1 (enExample) |
| JP (2) | JP7569688B2 (enExample) |
| CN (1) | CN112020500A (enExample) |
| AU (1) | AU2018388404B2 (enExample) |
| BR (1) | BR112020012635A2 (enExample) |
| CA (1) | CA3085366A1 (enExample) |
| IL (1) | IL275490B2 (enExample) |
| MX (1) | MX2020006587A (enExample) |
| RU (1) | RU2020124138A (enExample) |
| WO (1) | WO2019126731A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3085460A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| MX2020006587A (es) | 2017-12-22 | 2020-12-10 | Ravenna Pharmaceuticals Inc | Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. |
| AU2018392816B2 (en) | 2017-12-22 | 2023-04-20 | HiberCell Inc. | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| TW202112784A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN112441964A (zh) * | 2019-08-27 | 2021-03-05 | 北京奥得赛化学股份有限公司 | 一种制备4-异丙基吡啶的新方法 |
| CN111303195B (zh) * | 2020-04-07 | 2022-09-27 | 中国医学科学院放射医学研究所 | 一类含硼小分子化合物、其制备方法及应用 |
| CN112321494B (zh) * | 2020-11-17 | 2022-04-19 | 上海凌凯医药科技有限公司 | 一种制备2-氯-4-异丙基吡啶的方法 |
| CA3173777A1 (en) * | 2021-05-20 | 2022-11-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors and degraders of pip4k protein |
| TW202317106A (zh) * | 2021-08-27 | 2023-05-01 | 南韓商柳韓洋行 | 作為egfr抑制劑之取代胺基吡啶化合物 |
| TW202328096A (zh) | 2021-08-27 | 2023-07-16 | 南韓商柳韓洋行 | 作為egfr抑制劑之含五員雜芳基之胺基吡啶化合物 |
| EP4618755A1 (en) * | 2022-11-15 | 2025-09-24 | Larkspur Biosciences, Inc. | Inhibitors and degraders of pip4k protein |
| WO2024236595A1 (en) * | 2023-05-18 | 2024-11-21 | Council Of Scientific And Industrial Research | Protacs for ask1 protein degradation: preparation and use thereof |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| EP1690854A1 (en) | 1999-03-12 | 2006-08-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| EP1466906A1 (en) | 1999-03-12 | 2004-10-13 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| ID30176A (id) | 1999-03-12 | 2001-11-08 | Boehringer Ingelheim Pharma | Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi |
| AU773218B2 (en) | 1999-10-08 | 2004-05-20 | Debiopharm International Sa | Fab I inhibitors |
| US6703525B2 (en) | 2000-02-16 | 2004-03-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Sulfonamide intermediates and methods of producing same |
| US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| EP1560584B1 (en) | 2001-04-06 | 2009-01-14 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| EP1381594A1 (en) | 2001-04-13 | 2004-01-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Urea compounds useful as anti-inflammatory agents |
| WO2002096876A1 (en) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| EP1427412A1 (en) | 2001-09-13 | 2004-06-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of treating cytokine mediated diseases |
| AU2002341921B2 (en) | 2001-10-04 | 2007-05-31 | Merck Sharp & Dohme Corp. | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| US20050101518A1 (en) | 2002-01-18 | 2005-05-12 | David Solow-Cordero | Methods of treating conditions associated with an EDG-2 receptor |
| PL218692B1 (pl) | 2002-01-22 | 2015-01-30 | Warner Lambert Co | Podstawiony 2-(pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-on oraz jego zastosowanie do leczenia zaburzenia lub stanu spowodowanego nieprawidłową proliferacją komórek |
| JPWO2003062234A1 (ja) | 2002-01-23 | 2005-05-19 | 山之内製薬株式会社 | キノキサリン化合物 |
| US20040023961A1 (en) | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| WO2004030637A2 (en) | 2002-10-01 | 2004-04-15 | Merck & Co., Inc. | Treatment of obesity and other disorders associated with excessive food intake |
| ATE409485T1 (de) | 2003-03-17 | 2008-10-15 | Affinium Pharm Inc | Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend |
| BRPI0413757A (pt) | 2003-08-22 | 2006-10-31 | Boehringer Ingelheim Pharma | métodos para o tratamento de copd e da hipertensão pulmonar |
| US20070027321A1 (en) | 2003-09-02 | 2007-02-01 | Kamenecka Theodore M | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 |
| CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| JP4946861B2 (ja) | 2004-08-09 | 2012-06-06 | アステラス製薬株式会社 | ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物 |
| ES2338590T3 (es) | 2005-09-06 | 2010-05-10 | Glaxosmithkline Llc | Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos. |
| DE602006012694D1 (de) | 2005-09-06 | 2010-04-15 | Glaxosmithkline Llc | Benzimidazolthiophenverbindungen als plk-modulatoren |
| WO2007056023A2 (en) | 2005-11-02 | 2007-05-18 | Targegen, Inc. | Thiazole inhibitors targeting resistant kinase mutations |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| EP1968972B1 (en) | 2005-12-23 | 2012-11-28 | F. Hoffmann-La Roche AG | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| AU2007213018A1 (en) | 2006-02-07 | 2007-08-16 | Astellas Pharma Inc. | N-hydroxyacrylamide compounds |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| CN101384586A (zh) * | 2006-02-14 | 2009-03-11 | 诺华公司 | Pi-3激酶抑制剂及其应用方法 |
| US7855194B2 (en) | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
| US20100075960A1 (en) | 2006-06-02 | 2010-03-25 | Kevin Kuntz | Benzimidazole thiophene compounds |
| US7615643B2 (en) | 2006-06-02 | 2009-11-10 | Smithkline Beecham Corporation | Benzimidazole thiophene compounds |
| WO2007146712A2 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| DE102007007751A1 (de) | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0720444D0 (en) | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
| MX2010006457A (es) | 2007-12-19 | 2010-07-05 | Amgen Inc | Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular. |
| US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| CA2728016C (en) | 2008-06-24 | 2017-02-28 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
| US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
| EP2321309A1 (en) | 2008-06-25 | 2011-05-18 | Ranbaxy Laboratories Limited | Benzothiazoles and aza-analogues thereof use as antibacterial agents |
| CN102203083A (zh) | 2008-06-25 | 2011-09-28 | Irm责任有限公司 | 作为激酶抑制剂的嘧啶衍生物 |
| PE20110403A1 (es) | 2008-07-31 | 2011-07-04 | Genentech Inc | Compuestos biciclicos fusionados de pirimidina en el tratamiento del cancer |
| BRPI0917791B1 (pt) | 2008-08-22 | 2022-03-22 | Novartis Ag | Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação |
| US20110172217A1 (en) | 2008-09-05 | 2011-07-14 | Shionogi & Co., Ltd. | Ring-fused morpholine derivative having pi3k-inhibiting activity |
| GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| KR20120034592A (ko) | 2009-04-09 | 2012-04-12 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｈｉｖ 복제의 저해제 |
| KR101445458B1 (ko) | 2009-06-04 | 2014-10-07 | 노파르티스 아게 | １Ｈ-이미다조［４,５-ｃ］퀴놀리논 유도체 |
| CN102573486A (zh) | 2009-06-08 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
| EP2467137A1 (en) | 2009-08-19 | 2012-06-27 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
| WO2011021678A1 (ja) | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011031934A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| MX2012011912A (es) | 2010-04-13 | 2012-11-16 | Novartis Ag | Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer. |
| HUE027256T2 (en) | 2010-09-13 | 2016-08-29 | Novartis Ag | Triazine-oxadiazoles |
| WO2012045124A1 (en) | 2010-10-08 | 2012-04-12 | Biota Europe Ltd | Bacteria topoisomerase ii inhibiting 2-ethylcarbamoylamino-1, 3-benzothiazol-5-yls |
| WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
| CN102617548A (zh) | 2011-01-31 | 2012-08-01 | 北京赛林泰医药技术有限公司 | 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用 |
| JP2014513728A (ja) | 2011-05-17 | 2014-06-05 | プリンシピア バイオファーマ インコーポレイテッド | チロシンキナーゼ阻害剤としてのアザインドール誘導体 |
| US9216173B2 (en) | 2011-10-05 | 2015-12-22 | Merck Sharp & Dohme Corp. | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| EP2802576B1 (en) | 2012-01-13 | 2018-06-27 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| WO2013106641A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| CN104169275B (zh) | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
| HUE036582T2 (hu) | 2012-04-17 | 2018-07-30 | Fujifilm Corp | Nitrogéntartalmú heterociklusos vegyület vagy annak sója |
| US9376418B2 (en) | 2012-06-22 | 2016-06-28 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| CA2884766A1 (en) | 2012-10-16 | 2014-04-24 | Daniel Jon Burdick | Serine/threonine kinase inhibitors |
| WO2014106800A2 (en) | 2013-01-04 | 2014-07-10 | Aurigene Discovery Technologies Limited | Substituted 2-amino pyrimidine derivatives as kinase inhibitors |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| EP3029031A4 (en) | 2013-07-30 | 2017-01-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2015098991A1 (ja) | 2013-12-26 | 2015-07-02 | 東レ株式会社 | Ｎ－アルキルアミド誘導体及びその医薬用途 |
| WO2015112441A1 (en) | 2014-01-22 | 2015-07-30 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors |
| AU2015222865B2 (en) | 2014-02-28 | 2019-06-20 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| US10087195B2 (en) | 2014-05-28 | 2018-10-02 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
| WO2016015604A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| WO2016022644A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| WO2016027904A1 (ja) | 2014-08-22 | 2016-02-25 | 富士フイルム株式会社 | Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用 |
| EP3191467B1 (en) | 2014-09-12 | 2020-10-21 | Novartis AG | Compounds and compositions as kinase inhibitors |
| JP6672296B2 (ja) | 2014-10-31 | 2020-03-25 | ザ ジェネラル ホスピタル コーポレイション | 強力なγ−セクレターゼモジュレータ |
| WO2016089208A2 (en) | 2014-12-04 | 2016-06-09 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents |
| JP6884102B2 (ja) | 2015-02-09 | 2021-06-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための化合物 |
| EP3053577A1 (en) | 2015-02-09 | 2016-08-10 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| ES2930585T3 (es) | 2015-02-27 | 2022-12-19 | Nimbus Lakshmi Inc | Inhibidores de TYK2 y usos de los mismos |
| MX385083B (es) | 2015-04-14 | 2025-03-14 | Qurient Co Ltd | Derivados de quinolina como inhibidores de tirosinas-cinasas de receptor de met de axl, mer y tyro 3 (tam rtk). |
| LT3305785T (lt) | 2015-05-29 | 2021-11-10 | Teijin Pharma Limited | Pirido[3,4-d]pirimidino dariniai ir jų farmaciniu požiūriu priimtinos druskos |
| US10695346B2 (en) * | 2015-06-26 | 2020-06-30 | Dana-Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| MX382671B (es) | 2015-12-10 | 2025-03-13 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington |
| EP3386981B1 (en) | 2015-12-13 | 2021-10-13 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as anti-cancer agents |
| AU2017232610B2 (en) | 2016-03-16 | 2021-07-22 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
| AU2017254708B2 (en) | 2016-04-22 | 2021-09-16 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use |
| CN109476635B (zh) | 2016-04-29 | 2021-07-13 | Fgh生物科技公司 | 用于治疗疾病的二取代吡唑类化合物 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN112250669B (zh) | 2016-09-07 | 2022-02-25 | 江苏豪森药业集团有限公司 | 苯并咪唑类化合物激酶抑制剂及其制备方法和应用 |
| AU2017370694A1 (en) | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| WO2018136202A2 (en) | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
| CA3058182A1 (en) | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
| KR102444482B1 (ko) | 2017-04-01 | 2022-09-16 | 셍커 파마슈티컬스 (지앙수) 엘티디. | 단백질 인산화효소 억제제로서의 1h-이미다조[4,5-h]퀴나졸린 화합물 |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| CN109516989B (zh) | 2017-09-17 | 2021-12-31 | 上海美志医药科技有限公司 | 一类抑制并降解cdk的化合物 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| EP3707138B1 (en) | 2017-11-06 | 2022-07-13 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| MX2020006587A (es) | 2017-12-22 | 2020-12-10 | Ravenna Pharmaceuticals Inc | Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. |
| CA3085460A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| AU2018392816B2 (en) | 2017-12-22 | 2023-04-20 | HiberCell Inc. | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| AU2019216492A1 (en) | 2018-02-02 | 2020-08-20 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| AU2019220746A1 (en) | 2018-02-15 | 2020-08-27 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| US12037323B2 (en) | 2018-05-03 | 2024-07-16 | Bristol-Myers Squibb Company | Uracil derivatives as Mer-AXL inhibitors |
| LT3814357T (lt) | 2018-06-27 | 2024-06-25 | Ptc Therapeutics, Inc. | Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui |
| AU2019309909A1 (en) | 2018-07-23 | 2021-02-04 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use |
| BR122023024103A2 (pt) * | 2018-10-15 | 2024-02-20 | Nurix Therapeutics, Inc. | Compostos bifuncionais para degradação de btk por meio da via de proteossoma de ubiquitina, composição farmacêutica compreendendo os mesmos, e seus usos |
| DK3877052T3 (da) * | 2018-11-06 | 2023-09-25 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| WO2020109191A1 (en) | 2018-11-27 | 2020-06-04 | F. Hoffmann-La Roche Ag | Aryl compounds for the treatment and prophylaxis of bacterial infection |
| US12415797B2 (en) | 2018-11-30 | 2025-09-16 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic compound as CDK-HDAC double-channel inhibitor |
| US12358911B2 (en) | 2018-12-07 | 2025-07-15 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic comipound as CDK-HDAC dual pathway inhibitor |
| EP3891149A4 (en) | 2018-12-07 | 2022-09-07 | Sunshine Lake Pharma Co., Ltd. | RET INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| WO2020132700A1 (en) | 2018-12-21 | 2020-06-25 | Fgh Biotech Inc. | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof |
| AU2020204714A1 (en) | 2019-01-04 | 2021-07-08 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| EP3920918A4 (en) | 2019-02-05 | 2022-11-16 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| CN113661164B (zh) | 2019-04-08 | 2025-03-04 | 珠海宇繁生物科技有限责任公司 | 一种cdk激酶抑制剂及其应用 |
| CA3138973A1 (en) | 2019-05-05 | 2020-11-12 | Qilu Regor Therapeutics Inc. | Cdk inhibitors |
| AU2020277027A1 (en) | 2019-05-13 | 2021-12-09 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| TW202112784A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
-
2018
- 2018-12-21 MX MX2020006587A patent/MX2020006587A/es unknown
- 2018-12-21 JP JP2020554061A patent/JP7569688B2/ja active Active
- 2018-12-21 EP EP18836780.9A patent/EP3728228A1/en active Pending
- 2018-12-21 CN CN201880089919.9A patent/CN112020500A/zh active Pending
- 2018-12-21 AU AU2018388404A patent/AU2018388404B2/en active Active
- 2018-12-21 WO PCT/US2018/067264 patent/WO2019126731A1/en not_active Ceased
- 2018-12-21 RU RU2020124138A patent/RU2020124138A/ru unknown
- 2018-12-21 BR BR112020012635-7A patent/BR112020012635A2/pt not_active Application Discontinuation
- 2018-12-21 US US16/956,971 patent/US11667651B2/en active Active
- 2018-12-21 CA CA3085366A patent/CA3085366A1/en active Pending
- 2018-12-21 IL IL275490A patent/IL275490B2/en unknown
-
2023
- 2023-04-19 US US18/303,264 patent/US20240158415A1/en not_active Abandoned
-
2024
- 2024-01-31 JP JP2024013173A patent/JP2024056755A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL275490A (en) | 2020-08-31 |
| US11667651B2 (en) | 2023-06-06 |
| IL275490B1 (en) | 2024-01-01 |
| IL275490B2 (en) | 2024-05-01 |
| BR112020012635A2 (pt) | 2020-12-01 |
| JP2021506978A (ja) | 2021-02-22 |
| JP2024056755A (ja) | 2024-04-23 |
| AU2018388404A1 (en) | 2020-06-18 |
| AU2018388404B2 (en) | 2023-11-02 |
| JP7569688B2 (ja) | 2024-10-18 |
| CN112020500A (zh) | 2020-12-01 |
| CA3085366A1 (en) | 2019-06-27 |
| RU2020124138A (ru) | 2022-01-24 |
| US20240158415A1 (en) | 2024-05-16 |
| WO2019126731A1 (en) | 2019-06-27 |
| EP3728228A1 (en) | 2020-10-28 |
| US20210317136A1 (en) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020006587A (es) | Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. | |
| MX2020006613A (es) | Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa. | |
| MX2020006614A (es) | Derivados de cromenopiridina como inhibidores de fosfatidilinositol fosfato cinasa,. | |
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| PH12018501920B1 (en) | Bromodomain inhibitors | |
| PH12015502004A1 (en) | Tetracyclic bromodomain inhibitors | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| MX2015012005A (es) | Inhibidores de bromodominio. | |
| EA201890318A1 (ru) | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
| MX2016007346A (es) | Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio. | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| PH12012501768A1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
| EP4464317A3 (en) | Compounds and compositions and uses thereof | |
| NZ717825A (en) | Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid | |
| MX2016007440A (es) | Inhibidores del bromodominio. | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| AU2017269673A1 (en) | Pyridine dicarboxamide derivatives as bromodomain inhibitors | |
| SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
| MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
| MX2019004375A (es) | Inhibidores de bromodominios. | |
| MX2018005515A (es) | Derivados de 1,4-dicarbonil-piperidilo. | |
| MX2019004187A (es) | Inhibidores de bromodominios. |